Help
Subscribe


Submit Videos to GastroHep Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Contraindications to pegylated-interferon or ribavirin in HCV patients in the USA

A study published ahead of print in Alimentary Pharmacology & Therapeutics reports on contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic Hepatitis C.

News image

Chronic Hepatitis C treatment with pegylated-interferon ribavirin is often limited by preexisting medical, psychiatric and psychosocial contraindications.

However, limited data exist in general patient populations.

Dr Talal and colleagues from New York, USA evaluated the percentage of chronic Hepatitis C-infected patients in the general US population who may have contraindications to pegylated-interferon.

The General Electric Centricity dataset was used to screen the US population between 2004 and 2009 for chronic Hepatitis C infection and contraindications to  pegylated-interferon.

Chronic Hepatitis C diagnosis and contraindications were identified using ICD-9-CM codes or laboratory values.

The researchers reported that only patients with an encounter 180 days prior to chronic Hepatitis C diagnosis were included.

The team of doctors determined frequencies and percentages for absolute and relative contraindications to pegylated-interferon and/or ribavirin, and calculated proportions and rates per 1000 person-months.

17% had at least one contraindication to pegylated-interferon
Alimentary Pharmacology & Therapeutics

A total of 15,561,021 patients were screened, and 45,690 who were chronic Hepatitis C-positive were evaluated.

The research team observed that those with contraindications were significantly younger, female, White, not currently married and receiving Medicare or Medicaid coverage.

The team observed that 17% had at least one contraindication to pegylated-interferon, including bipolar disorder, anemia, pregnancy, and neutropenia.

Dr Talal's team concludes, "Approximately, 17% of chronic Hepatitis C-infected patients in the general US population had at least one contraindication to pegylated-interferon."

"Most contraindications were relative and potentially modifiable."

"Clinical assessment of contraindications as relative and/or modifiable should be considered and used to determine if patients could benefit from current pegylated-interferon–containing triple therapy or future pegylated-interferon– or ribavirin-free regimens."

Aliment Pharmacol Ther 2013: 37(4): 473–481
24 January 2013

Go to top of page Email this page Email this page to a colleague

 30 May 2015

Advanced search
 29 May 2015 
Comfort during colonoscopy
 29 May 2015 
Colorectal neoplasia in liver transplant candidates
 29 May 2015 
Cervical cancer with immunosuppressive therapy in IBD
 28 May 2015 
Excercise and IBD
 28 May 2015 
Probiotics and Crohn's disease
 28 May 2015 
Bleeding and colorectal endoscopic submucosal dissection
 27 May 2015 
Vegetables and fruit and IBD
 27 May 2015 
Radiofrequency ablation for treatment of GERD
 27 May 2015 
Management of constipation and IBS
 26 May 2015 
Antimicrobials for intraabdominal infection
 26 May 2015 
Calcium channel blockers and GI bleeds
 26 May 2015 

Risk factors for celiac disease

 25 May 2015 
Colorectal cancer screening
 25 May 2015 
Saccharomyces boulardii and H. pylori
 25 May 2015 
Risk of GI bleeds with NSAIDs
 22 May 2015 
Colonoscopy screening for colorectal cancer
 22 May 2015 
Treatment with anti-integrin antibodies in IBD
 22 May 2015 
Care of patients with GERD
 21 May 2015 
Lymphoma in IBD
 21 May 2015 
Serrated polyps and colorectal cancer
 21 May 2015 
Imaging for hepatocellular carcinoma
 20 May 2015 
Pancreatic neuroendocrine tumors
 20 May 2015 
Surveillance in long-segment Barrett's
 20 May 2015 
Refractory metastatic colorectal cancer
 19 May 2015 
Metabolic syndrome and Barrett's
 19 May 2015 
PPIs and cryptogenic liver abscess
 19 May 2015 
Anti-integrin antibodies in IBD
 18 May 2015 
ESPGHAN celiac guidelines
 18 May 2015 
HLA haplotypes and primary sclerosing cholangitis
 18 May 2015 
Safety of PPI
 15 May 2015 
Microscopic colitis risk with PPIs/NSAIDs
 15 May 2015 
Management of nonhospitalized ulcerative colitis
 15 May 2015 
Diabetes and infections in IBD with immunomodulation
 14 May 2015 
Diagnosis of spontaneous bacterial peritonitis
 14 May 2015 
Mortality in US patients with cirrhosis
 14 May 2015 
Radiation exposure during ERCP
 13 May 2015 
Predictors of IBD
 13 May 2015 
Psychological distress and liver disease mortality
 13 May 2015 
Hypnotherapy in IBS/IBD
 12 May 2015 
Bleeding in NSAID users with H.pylori
 12 May 2015 
Capsule colonoscopy detects colorectal polyps
 12 May 2015 
Anti-TNF biologics in acute severe ulcerative colitis
 11 May 2015 
Management of Barrett's esophagus
 11 May 2015 
Marker to detect recurrence of Crohn's
 11 May 2015 
Thalidomide for IBD
 08 May 2015 
Surveillance colonoscopy in colorectal cancer
 08 May 2015 
HCV treatment with compensated cirrhosis
 08 May 2015 
Medical management of Crohn's
 07 May 2015 
Surgical complications in ulcerative colitis
 07 May 2015 
Combination therapy for noncirrhostic patients
 07 May 2015 
Anxiety and new-onset dyspepsia
 06 May 2015 
PPIs and spontaneous bacterial peritonitis
 06 May 2015 
Infant feeding and celiac disease
 06 May 2015 
Preventing recurrent C. diff infection
 05 May 2015 
Fatigue in primary sclerosing cholangitis
 05 May 2015 
Annual CT scans after esophagectomy for cancer
 05 May 2015 
Prevalence of eosinophilic esophagitis
 04 May 2015 
Stress resilience and peptic ulcer disease
 04 May 2015 
Endoscope storage and microbial colonization
 04 May 2015 
Menarche and NAFLD

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us